Patent · US Active

Heterocyclic compound

US12084436B2 · kind B2 · utility

0Cited by

0References

16Claims

0Family size

Assignee

Takeda Pharmaceutical Company Limited · JP

Inventors

Masahiro Ito · Chiyoda, JP
Takeshi Yamamoto · Kashiwara, JP
Keiko Kakegawa · Yokohama, JP
Hideyuki Sugiyama · Yokohama, JP
Tohru Miyazaki · Osaka, JP
Yasuyoshi Arikawa · Osaka, JP
Tomohiro Okawa · Yokohama, JP
Jinichi Yonemori · Yokohama, JP
Osamu Kubo · Osaka, JP
Akinori TOITA · Yokohama, JP
Takuto Kojima · Osaka, JP
Fumiaki Kikuchi · Yokohama, JP
Minoru Sasaki · Yokohama, JP
Misaki Homma · Yokohama, JP
Yasuhiro Imaeda · Ann Arbor, US
Hironobu Maezaki · Yokohama, JP
Shiinobu Sasaki · Yokohama, JP
Ayumu Sato · Yokohama, JP
Hirotaka KAMITANI · Yokohama, JP
Yasutomi Asano · Yokohama, JP
Hironori Kokubo · Yokohama, JP
Masato Yoshikawa · Yokohama, JP

Key dates

Filing date	Jan 29, 2020
Grant date	Sep 10, 2024
Priority date	—
Expiry date	Oct 11, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D471/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.